Osteopontin polymorphisms and disease course in multiple sclerosis

[1]  A. Alderborn,et al.  Pyrosequencing™ technology and the need for versatile solutions in molecular clinical research , 2002, Expert review of molecular diagnostics.

[2]  M. Permutt,et al.  Assessing allele frequencies of single nucleotide polymorphisms in DNA pools by pyrosequencing technology. , 2002, BioTechniques.

[3]  Jorge R. Oksenberg,et al.  The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease , 2001, Science.

[4]  E R Martin,et al.  Letter to the Editor Correcting for a Potential Bias in the Pedigree Disequilibrium Test , 2022 .

[5]  Stephen L Hauser,et al.  Multiple sclerosis: Genomic rewards , 2001, Journal of Neuroimmunology.

[6]  G. Nau,et al.  Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. , 2000, Immunology today.

[7]  E. Martin,et al.  A test for linkage and association in general pedigrees: the pedigree disequilibrium test. , 2000, American journal of human genetics.

[8]  M. Glimcher,et al.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. , 2000, Science.

[9]  D. Clayton,et al.  A generalization of the transmission/disequilibrium test for uncertain-haplotype transmission. , 1999, American journal of human genetics.

[10]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[11]  H T Mount,et al.  Multiple sclerosis and other demyelinating diseases. , 1973, Canadian Medical Association journal.

[12]  J. Haines,et al.  Genetic basis for clinical expression in multiple sclerosis. , 2002, Brain : a journal of neurology.